{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Systemic+Sclerosis&page=7",
    "query": {
      "condition": "Progressive Systemic Sclerosis",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 187,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Systemic+Sclerosis&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Systemic+Sclerosis&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T00:37:16.716Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04915950",
      "title": "A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Temanogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-03",
      "completion_date": "2022-09-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04915950"
    },
    {
      "nct_id": "NCT06329401",
      "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "Progressive Pulmonary Fibrosis",
        "Pulmonary Fibrosis Secondary to Systemic Sclerosis",
        "Pulmonary Fibrosis, Interstitial Lung Disease",
        "Interstitial Lung Disease",
        "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",
        "Interstitial Lung Disease in Patients With Rheumatoid Arthritis",
        "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere",
        "Hypersensitivity Pneumonitis",
        "Interstitial Lung Disease With Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Avalyn Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 398,
      "start_date": "2024-04-03",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329401"
    },
    {
      "nct_id": "NCT05455437",
      "title": "Monitoring and Evaluation Study of Project ECHO for ILD",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Interstitial Lung Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pulmonary Care and Research Collaborative Limited",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2022-07",
      "completion_date": "2024-03",
      "has_results": false,
      "last_update_posted_date": "2022-07-13",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05455437"
    },
    {
      "nct_id": "NCT00725361",
      "title": "A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "n Ulcer",
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-31",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00725361"
    },
    {
      "nct_id": "NCT05925803",
      "title": "Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Anifrolumab (blinded)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo (blinded)",
          "type": "DRUG"
        },
        {
          "name": "Anifrolumab (unblinded, open label)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 314,
      "start_date": "2023-11-08",
      "completion_date": "2028-04-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05925803"
    },
    {
      "nct_id": "NCT04402086",
      "title": "Rheumatology Patient Registry and Biorepository",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatic Diseases",
        "Adult Onset Still Disease",
        "Ankylosing Spondylitis",
        "Psoriatic Arthritis",
        "Reactive Arthritis",
        "Antiphospholipid Syndrome",
        "Systemic Lupus Erythematosus",
        "Behcet Disease",
        "Dermatomyositis",
        "Polymyositis",
        "Giant Cell Arteritis",
        "Lyme Disease",
        "Mixed Connective Tissue Disease",
        "Polymyalgia Rheumatica",
        "Rheumatoid Arthritis",
        "Sarcoidosis",
        "Systemic Sclerosis",
        "Scleroderma",
        "Sjogren's Syndrome",
        "Undifferentiated Connective Tissue Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 5000,
      "start_date": "2020-08-04",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402086"
    },
    {
      "nct_id": "NCT06716606",
      "title": "A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Connective Tissue Diseases"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2024-12-12",
      "completion_date": "2030-10-23",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06716606"
    },
    {
      "nct_id": "NCT01697254",
      "title": "The CARRA Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Juvenile Idiopathic Arthritis",
        "Systemic Lupus Erythematosus",
        "Mixed Connective Tissue Disease",
        "Juvenile Ankylosing Spondylitis",
        "Juvenile Dermatomyositis",
        "Localized Scleroderma",
        "Systemic Sclerosis",
        "Vasculitis",
        "Sarcoid",
        "Fibromyalgia, Primary",
        "Auto-inflammatory Disease",
        "Idiopathic Uveitis Idiopathic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9587,
      "start_date": "2009-08",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-17",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697254"
    },
    {
      "nct_id": "NCT00853788",
      "title": "Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-11",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-02-17",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853788"
    },
    {
      "nct_id": "NCT01532869",
      "title": "A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sclerosis, Systemic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab [RoActemra/Actemra]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2012-03",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-22T00:37:16.716Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • San Diego, California • Stanford, California + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01532869"
    }
  ]
}